



SymBio Pharmaceuticals Limited
San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 <http://www.symbiopharma.com/>

December 11, 2009
SymBio Pharmaceuticals Limited.
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

SymBio Pharmaceuticals Limited Announces Completion of Third Party Allocation of New Shares

TOKYO, Japan, December 11, 2009 -- SymBio Pharmaceuticals Limited ("SymBio") today announced that as part of its Series D round of financing, the Company has completed the third-party allocation of new shares to a maximum value of 1.5 billion yen (25,000 shares), resolved at an extraordinary shareholders' meeting held on August 21, 2009, to WERU Investment, Cephalon, Inc., and four new shareholders. The higher than expected level of interest by new investors has led to an oversubscription of shares, with plans to extend the number of new shares for allocation in this round by the end of the year.

Using funds raised, SymBio will continue to increase its value to shareholders through the development of quality drug candidates in its pipeline.

[SyB L-0501]

SymBio holds exclusive rights to SyB L-0501, the Company's first drug candidate, from Astellas Deutschland GmbH for development and commercialization in Japan, China (HK), Taiwan, Korea and Singapore, and is actively building partnerships through the execution of license agreements with quality companies in each country in order to bring bendamustine hydrochloride to Asian markets as expeditiously as possible. The drug is already listed in the NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology, the recognized standard for clinical policy in oncology.

On October 30, the Company submitted its New Drug Application to the Pharmaceuticals and Medical Devices Agency for SyB L-0501 for the treatment of refractory and relapsed low-grade non-Hodgkin's lymphoma and mantle cell lymphoma.

[Company Profile]

SymBio Pharmaceuticals Ltd. was established in March, 2005 by Fuminori Yoshida, who previously served as both Corporate VP of Amgen Ltd. and President of Amgen Japan (currently Takeda Bio Development Center Limited). The company's underlying corporate mission is "delivering hope to patients in need", aspiring to be a leading specialty pharmaceutical company in the Asia Pacific Rim dedicated to addressing underserved medical needs in the areas of oncology and hematology.

[Contact]

SymBio Pharmaceuticals Limited.

Hiroki Maekawa,

Corporate Officer,

Head of Corporate Division

Tel: +081(0)3 5472 1125

e-mail: Please send your inquiry through "INQUIRY" in our homepage

URL: <http://www.symbiopharma.com>